ClinicalTrials.gg
RecruitingNCT05198271DISRUPT-estRAUpdated Sep 8, 2023

Effect of Controlling Environmental Risk Factors in Established RA

An interventional study of Management of risk factors and Smoking cessation in Rheumatoid Arthritis, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.

Planned enrollment
14th of 15
25 · median 87
Started
2022
with 1 other
No phase
13 of 27
2 open now
Registered
20th of 27
by date

Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, and was the 20th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, or all of them as a file.
02

Study summary

  • The factors contributing to the development of rheumatoid arthritis are multiple, with a role of the environment and a predisposing genetic background.
  • Among the modifiable environmental factors :unbalanced diet, overweight, low physical activity, smoking, periodontal disease, stress have been identified as risk factors for developing RA.
  • By causing low-grade inflammation and stimulation of the immune system (particularly through adipokines, citrullination phenomena and changes in the microbiota), these factors promote the onset of the disease and could also participate in the maintenance of inflammatory processes.
  • Thus, obese subjects have more active RA, a lower therapeutic response, and weight loss is associated with lower disease activity ; sedentary lifestyle is associated with more active RA and increased physical activity has beneficial effects on RA; people who smoke respond less well to treatment; periodontal disease is associated with more active RA and their treatment is associated with a decrease in this activity.
  • Finally, different methods having a beneficial impact on stress (mindfulness meditation, yoga, relaxation, etc.) have shown interesting results in patients with RA.
  • It is important to note that all of these factors are also associated with an increased cardiovascular risk, the leading cause of death in RA.
  • The combination of these factors probably has synergistic effects and it is therefore relevant to propose a correction of all these factors in the same program.
  • We have developed a management program for environmental risk factors for RA based with experts including rheumatologists, nutritionists, smoking cessation specialists, periodontal disease specialists and stress specialists.
Read the detailed description

Methodology:

  • We will conduct a Phase 2 to one phase trial with A'Hern design.
  • The patients included will have RA (ACR / EULAR 2010 criteria), with an active disease (2.6 \<DAS 28 \<5.1), and at least 3 risk factors among: BMI ≥25 kg / m², low physical activity , active smoking, periodontitis and anxiety.

    1. The primary endpoint will be the number of patients for whom at least 2 or 3 risk factors (depending on whether 3 present or 4-5 present at baseline) are corrected / in the process of being corrected at 6 months.
    2. The secondary endpoints will be:

A) Acceptability: number of patients agreeing to participate in the protocol / total number of screened patients fulfilling the inclusion criteria; questionnaires with EVA carried out at the end of the program; Membership of the program: online completion of questionnaires, use of the accelerometer, participation in teleconsultations and organized group sessions.

B) For each risk factors: number of patients who corrected it at 3 and 6 months.

C) RA activity measured by DAS28-CRP + RAID questionnaire, biological markers

D) Distribution of the different germs of the oral and faecal micobiota and diversity.

  • As risks factor are established chronically, we hypothesize that only 10% of patients would correct at least 2 or 3 risk factors over 6 months in the absence of intervention. The expected efficiency is 40%.
  • By recruiting 25 patients, we will have a power of 90% to demonstrate that the one-sided 95% confidence interval of the effectiveness of the intervention is greater than 10% (p (0) if the true value of effectiveness is 35% (p (1)). This demonstration will be made if 6 patients out of 25 are successful.

Procedure:

  • 3 visits will be necessary for rheumatological and biological evaluations (inclusion +/- M0, M3 and M6).
  • All patients will have 2 periodontal visits (M0 and M6 for evaluation and scaling). Those with periodontitis will have other visits depending on the care to be performed.
  • The smoking patients will have teleconsultations (TC) with a tobacco specialist (S0, S4 and S8 then according to tobacco specialist).
  • All patients will have a TC with a dietitian (45 min 1st consultation with set goals) and those overweight will then have a TC every 15 days for 3 months.
  • All patients will have a TC with a sports doctor (assessment of physical activity and development of a personalized program, explanation of the pedometer provided). For those with low physical activity, a virtual group session of 45 min / week will be organized.
  • Patients with anxiety will have TC with a psychiatrist specializing in stress management, with training in the use of cardiac coherence from connected equipment given to the patient.
  • All the interventions will be coordinated on an existing platform (MyGoodLife) which allows the dietary assessment, the automatic report of connected objects (pedometer) and the organization of group sessions.
03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • prevention
  • smoking
  • diet
  • periodontitis
  • physical activity
  • stress
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RA (ACR / EULAR 2010 criteria), with an active disease (2.6 \<DAS 28 \<5.1)
  • Basis treatment for at least 3 months and corticoids \<= 10mg / day

And at least 3 risk factors among:

  • ≥25 kg / m²
  • Low physical activity (IPAQ short version)
  • Active smoking
  • Periodontitis ( bone loss on dental panoramic)
  • Anxiety ( Beck anxiety Index > 16)

Exclusion criteria

Exclusion Criteria:

  • Patient under protective measure or unable to consent
  • Patient for whom a change in basic treatment for RA is planned within 6 months
  • Active cancer
  • Active infection
  • Antibiotic therapy in the previous 3 months
  • No health cover
  • Diabetes
  • Unbalanced psychiatric pathologies
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Management of risk factors

    -6 month program for reduction /correction of risk factors in patient with active RA : 1. Smoking cessation 2. weightloss 3. Increased physical activity 4. Periodontal treatment 5. Decreased anxiety

    Other: Management of risk factors · Behavioral: Smoking cessation · Behavioral: weightloss · Other: periodontal disease treatment · Behavioral: increased physical activity · Behavioral: Decreased anxiety

Interventions

  • OtherManagement of risk factors

    * For all patients: * Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6 * Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling * Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report. * Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)

  • BehavioralSmoking cessation

    - For active smoking patients: * Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist * Nicotine substitutes +/- varenicline according to tobacco consumption * Online notebook to record tobacco consumption and "triggers"

  • Behavioralweightloss

    -For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve

  • Otherperiodontal disease treatment

    - For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6

  • Behavioralincreased physical activity

    - For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months

  • BehavioralDecreased anxiety

    - For anxious patients: * Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence * Delivery of connected equipment for the practice of cardiac coherence

06

What researchers measure

Primary outcomes

  1. Estimate the effectiveness at 6 months of this program on the overall reduction / correction of risk factors.

    Number of patients for whom at least 2 or 3 risk factors (depending on whether 3 present or 4-5 present at baseline) are corrected / in the process of correction. Risk factors will be considered corrected / in the process of being corrected if: * Weight loss ≥5% of initial weight at 6 months (objective measurement of weight) and / or BMI at 6 months \< 25kg/m² * Complete smoking cessation (declarative assessment) * Correction of sedentary lifestyle with moderate to strong IPAQ AND increase of ≥2,000 steps / day compared to the initial assessment (on average 5 days / 7) (questionnaire and quantified assessment obtained with the pedometer and automatically reported on the platform) * Improvement in periodontal disease scores ≥4 points on 6 teeth assessed according to Ramfjord's recommendation (plaque index (Sillness and Loe index), gingival (Lobene index) and papillary bleeding index) (evaluation by the periodontologist) * Decrease in anxiety score from N class to N-1 class

    Time frame: 6 MONTHS

Secondary outcomes

  1. To assess the acceptability and adherence of RA patients to the intervention program.

    * Acceptability: * number of patients agreeing to participate in the protocol / total number of screened patients fulfilling the inclusion criteria. * questionnaire with different visual analog scales carried out at the end of the program. * Adherence: assessed by completing online questionnaires / weight, using the accelerometer, participating in various teleconsultations and organized group sessions

    Time frame: 6 MONTHS

  2. At least two risk factors (if 3 present at base) or at least three (if 4 or 5 present at base) are corrected / in the process of correction.

    same description as for the outcome 1

    Time frame: 3 MONTHS

  3. RA activity

    DAS 28-CRP, RAID, biological markers (FR, ACPA, CRP)

    Time frame: 3 MONTHS, 6 MONTHS

  4. Distribution of the different germs of the oral and fecal micobiota and alpha and beta diversity

    targeted metagenomics 16s RNA

    Time frame: 3 MONTHS, 6 MONTHS

  5. Personality traits assessed by the Minnesota Multiphasic Personality Inventory questionnaire (MMPI)

    Time frame: MONTH 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jul 2024, 26 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 26 months is close to that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 20, 2022
StartActual
May 31, 2022
Primary completionEst.
Jul 2024
CompletionEst.
Jan 2025
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05198271
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
May 31, 2022
Primary completion
Jul 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Sep 8, 2023

Study contacts

Claire DAIEN, MD
Contact
c-daien@chu-montpellier.fr
+33467337794
Claire DAIEN, MD
study director · UH of Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion